Allergan's Semprana and CoLucid's Lasmiditan, Two Novel Acute Migraine Therapies, Will Drive Market Growth Through 2023

BURLINGTON, Mass., Nov. 20, 2014 /PRNewswire/ -- Decision Resources Group finds that the overall migraine market will grow from approximately $3 billion in 2013 to over $5 billion in 2023 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan, with an average annual growth rate of 5.8 percent. This growth will occur mainly in the second half of the 2013-2023 forecast period and will be driven largely by the launch of two nontriptan acute therapies: Allergan's orally inhaled dihydroergotamine product Semprana (launching in the United States in 2016), and CoLucid's 5HT1F receptor agonist lasmiditan (launching in the major markets beginning in 2018). Decision Resources Group projects that, together, these two therapies will earn nearly $1.5 billion in major-market sales in 2023 and will serve a subset of patients seeking nontriptan therapies due to non-response or to cardiovascular risks.

Other key findings from the Pharmacor report entitled Migraine:

• Launch of five triptan reformulations will offset generic erosion of the triptan class: Multiple non-tablet triptan reformulations are expected to launch during the forecast period: Teva's Zecuity (sumatriptan transdermal patch), Avanir Pharmaceuticals/OptiNose's AVP-825 (sumatriptan intranasal powder), Applied Pharma Research/tesa Labtech's zolmitriptan oral dispersible film (ODF), IntelGenX/RedHill Biopharma's Rizaport (rizatriptan ODF) and Suda's SUD-001 (sumatriptan oral spray). These emerging triptan products together will earn more than $800 million in major-market sales in 2023 and will help offset a decline in sales as the remaining branded triptans become generically available through 2017.
• Allergan's Botox continues to drive growth in the prophylactic market: Physicians are becoming increasingly comfortable with prescribing Botox to their patients with chronic migraine, especially given Botox's very favorable tolerability profile and few undesirable side effects, compared to other prophylactic options. Increasing use of Botox will be a key driver of over 6 percent annual growth in migraine prophylactic sales through 2023.
• Remaining unmet need for prophylactic therapies in migraine: The drug development pipeline is dominated by acute treatments, leaving sizable opportunity for developers to address the need for more efficacious prophylactic drugs with reduced side effects.

Comments from Decision Resources Group Analyst Angela Sparrow, Ph.D.:

• "Given the large acutely-treated migraine patient population, high-priced acute therapies targeting niche groups can still garner considerable market share while capturing only a small percentage of the patient share."
• "Despite the unmet need for new prophylactic migraine therapies, no such treatments are likely to launch in the near term. However, one emerging class of prophylactic treatments that is garnering excitement from interviewed experts is the calcitonin gene-related peptide-targeted therapies; though still early in development, these therapies represent a truly novel approach to migraine prophylaxis."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
[email protected]

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO 

SOURCE Decision Resources Group

Related Links

http://www.decisionresourcesgroup.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED